Application of brief ultra-short high voltage pulses to tissue may generate high electric fields in tissue to generate a local region of ablated tissue by the biophysical mechanism of irreversible electroporation.
In cardiac applications, high voltage pulses, however, may cause complications such as induced arrhythmias (e.g., ventricular fibrillation) if delivered during certain periods of cardiac activity. Accordingly, it can be desirable to delivery high voltage pulses for pulsed electric field ablation in synchrony with the cardiac cycle so as to avoid the risk of such complications,
Described herein are systems, devices, and methods for detecting ectopic cardiac activity in connection with delivery of ablation energy to tissue such as pulsed electric field ablation. Pulsed electric field ablation uses ultra-short high-voltage pulses to generate large electric fields at desired regions of interest to generate a local region of ablated tissue via irreversible electroporation. In certain applications, including cardiac applications, it can be desirable to generate pulses for pulsed electric field ablation in synchronicity with a cardiac cycle. Synchronizing ablation energy delivery with the cardiac cycle may reduce the risk of induced arrhythmias such as atrial and/or ventricular fibrillation. One method of synchronizing delivery of pulses can be to pace of stimulate one or more cardiac cambers with periodic pacing signals with a predefined time period. For example, a cardiac stimulator may be used to deliver pacing pulses to one or more cardiac chambers such that the cardiac rhythm of a patient synchronizes with the pacing pulse. In some embodiments, pacing pulses can be delivered to the cardiac chamber(s) via an intracardiac catheter that is suitably positioned in the chamber(s). The intracardiac catheter can include one or more electrodes that are used to conduct the pacing signal into the heart. For example, the catheter can have a pair of electrodes (e.g., a most distal electrode and an electrode proximal to the distal electrode) that is used as a bipolar pair to deliver a pacing signal, with the two electrodes providing the forward and return current paths for the pacing signal. The pacing pulse can cause the cardiac chamber to generate its electrocardiogram (ECG) pulses in synchrony with the pacing pulses, thereby controlling the timing of the cardiac cycle.
Once the periodicity of the cardiac cycle is established and confirmed, e.g., by a physician, the delivery of high voltage ablation pulses can be timed to start in synchrony with the pacing signals. For example, the ablation pulses can be delivered with predetermined offsets from the pacing signals such that their delivery falls within the refractory window following the QRS waveform of the cardiac cycle. In some embodiments, the ablation pulses can be delivered to a cardiac chamber using an ablation catheter configured for pulsed electric field ablation.
While a cardiac chamber is being paced, however, localized electrical activity (e.g., pre-ventricular contraction (PVC)) may trigger ectopic cardiac activity that generates an additional localized T-wave (e.g., ectopic beat) that may overlap the next pacing pulse. Ablation energy delivered during these localized T-waves may have a high risk of inducing fibrillation.
Accordingly, it can be desirable to detect such localized or ectopic ECG activity that can occur between successive pacing pulses during ablation, such that the ablation system can ensure that ablation is not delivered during those times. For example, an ablation device can be configured to be disconnected from a signal generator when ectopic activity has been detected. By disconnecting or switching off the ablation device (for example, with a suitable relay), the risk of inducing a fibrillation event can be reduced.
Systems, devices, and methods described herein can be configured to detect ectopic signals and to control the operation of an ablation device based on such detection. For example, a system as described herein may include a cardiac stimulator and pacing device used to electrically pace the heart and ensure pacing capture to establish periodicity and predictability of the cardiac cycle. The pacing device may be configured to measure electrical cardiac activity (e.g., an electrocardiogram (ECG) signal) used to confirm pacing capture and/or detect ectopic cardiac activity. For example, predetermined portions of an ECG signal may be analyzed for an ectopic beat and synchronization between a pacing pulse and cardiac cycle. A cardiac activity status may be output to indicate the status of pacing capture and/or ectopic cardiac activity, and be used to control delivery of ablation energy to tissue.
The system may further include a signal generator and a processor configured to apply one or more voltage pulse waveforms to a selected set of electrodes of an ablation device to deliver energy to a region of interest (e.g., ablation energy for a set of tissue in a pulmonary vein ostium). The pulse waveforms disclosed herein may aid in therapeutic treatment of a variety of cardiac arrhythmias (e.g., atrial fibrillation).
The cardiac stimulator may synchronize the generation of the pulse waveform to a paced heartbeat in order to reduce unintended tissue damage. For example, a time window within a refractory period of the periodic cardiac cycle may be selected for voltage pulse waveform delivery. Thus, voltage pulse waveforms may be delivered in the refractory period of the cardiac cycle so as to avoid disruption of the sinus rhythm of the heart. The pulse waveform may be generated based on a cardiac activity status indicating an absence of an ectopic beat and confirmation of pacing capture. For example, the pulse waveform may be generated in synchronization with a pacing signal of the heart to avoid disruption of the sinus rhythm of the heart, and can be delivered outside of periods of detected ectopic activity. The pulse waveform can be delivered to one or more electrodes of one or more catheters that are epicardially or endocardially placed around the heart, such that those electrodes generate a pulsed electric field to ablate tissue. In some embodiments, the pulse waveform may include hierarchical waveforms to aid in tissue ablation and reduce damage to healthy tissue.
In some embodiments, an apparatus includes a memory and a processor operatively coupled to the memory. The processor can be configured to receive cardiac signal data captured by a set of electrodes; extract a sliding window of the cardiac signal data; identify a peak frequency over a subrange of frequencies associated with the extracted sliding window; detect ectopic activity based at least on a measure of the peak frequency over the subrange of frequencies; and in response to detecting ectopic activity, send an indication of ectopic activity to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator is deactivated or switched off from generating the pulsed waveforms.
In some embodiments, an apparatus includes a memory and a processor operatively coupled to the memory. The processor can be configured to receive cardiac signal data captured by a set of electrodes; receive an indication of delivery of a set of pacing pulses to the cardiac tissue; extract portions of the cardiac signal data following delivery of a subset of successive pacing pulses from the set of pacing pulses; calculate, for each extracted portion, a set of moments of a function associated with that extracted portion; confirm pacing capture of the set of pacing pulses based at least on the set of moments calculated for each extracted portion; and in response to confirming pacing capture, send an indication of pacing capture to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator is activated for generating the pulsed waveforms. In some embodiments, the processor is further configured to: analyze local peak frequencies of the cardiac signal data to detect ectopic activity; and in response to detecting ectopic activity, send an indication of ectopic activity to the signal generator such that the signal generator is switched off from generating the pulsed waveforms.
In some embodiments, a system includes a first controller configured to generate a pulsed waveform and deliver the pulsed waveform in synchrony with a set of pacing pulses to an ablation device; and a second controller operatively coupled to the first controller, the second controller configured to: generate the set of pacing pulses and deliver the set of pacing pulses to a pacing device; receive cardiac signal data captured by a set of electrodes; confirm pacing capture of the set of pacing pulses based on the cardiac signal data; and in response to confirming pacing capture, send an indication of pacing capture to the first controller to activate generation of the pulsed waveform. In some embodiments, the second controller is further configured to: monitor the cardiac signal data for ectopic activity; and when ectopic activity is present, send an indication of ectopic activity to the first controller to switch off generation of the pulsed waveform.
In some embodiments, a method includes receiving cardiac signal data captured by a set of electrodes disposed near cardiac tissue; extracting a sliding window of the cardiac signal data; identifying a peak frequency over a subrange of frequencies associated with the extracted sliding window; detecting ectopic activity based at least on a measure of the peak frequency over the subrange of frequencies; and in response to detecting ectopic activity, sending an indication of ectopic activity to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator is switch off from generating the pulsed waveforms. The method can further include confirming pacing capture of the set of pacing pulses based on the cardiac signal data.
The term “electroporation” as used herein refers to the application of an electric field to a cell membrane to change the permeability of the cell membrane to the extracellular environment. The term “reversible electroporation” as used herein refers to the application of an electric field to a cell membrane to temporarily change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing reversible electroporation can observe the temporary and/or intermittent formation of one or more pores in its cell membrane that close up upon removal of the electric field. The term “irreversible electroporation” as used herein refers to the application of an electric field to a cell membrane to permanently change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing irreversible electroporation can observe the formation of one or more pores in its cell membrane that persist upon removal of the electric field.
Pulse waveforms for electroporation energy delivery as disclosed herein may enhance the safety, efficiency and effectiveness of energy delivery to tissue by reducing the electric field threshold associated with irreversible electroporation, thus yielding more effective ablative lesions with a reduction in total energy delivered. In some embodiments, the voltage pulse waveforms disclosed herein may be hierarchical and have a nested structure. For example, the pulse waveform may include hierarchical groupings of pulses having associated timescales. In some embodiments, the methods, systems, and devices disclosed herein may comprise one or more of the methods, systems, and devices described in International Application Serial No. PCT/US2019/014226, filed on Jan. 18, 2019, published as International Publication No. WO/2019/143960 on Jul. 25, 2019, and titled “SYSTEMS, DEVICES AND METHODS FOR FOCAL ABLATION,” the contents of which are hereby incorporated by reference in its entirety.
Disclosed herein are systems and devices configured for monitoring ectopic cardiac activity in connection with tissue ablation via the selective and rapid application of voltage pulse waveforms resulting in irreversible electroporation. Generally, a system for ablating tissue described here may include a cardiac stimulator for generating a pacing signal delivered by a pacing device to the heart. The system further measures electrical cardiac activity for identification of ectopic beats and/or to confirm pacing capture of the heart. The detected pacing signal and/or detected cardiac activity can be used to control delivery of a pulse waveform generated by a signal generator to an ablation device having one or more electrodes. As described herein, the systems and devices may be deployed epicardially and/or endocardially to treat heart conditions such as, for example, atrial fibrillation. Voltages may be applied to a selected subset of the electrodes, with independent subset selections for anode and cathode electrode selections.
Generally, the systems and devices described herein include one or more devices (e.g., catheters) configured to ablate tissue in a left atrial chamber of a heart.
Each of the one or more processor(s) (124) may be any suitable processing device configured to run and/or execute a set of instructions or code. The processor may be, for example, a general purpose processor, a Field Programmable Gate Array (FPGA), an Application Specific Integrated Circuit (ASIC), a Digital Signal Processor (DSP), and/or the like. The processor may be configured to run and/or execute application processes and/or other modules, processes and/or functions associated with the system and/or a network associated therewith (not shown). The underlying device technologies may be provided in a variety of component types, e.g., metal-oxide semiconductor field-effect transistor (MOSFET) technologies like complementary metal-oxide semiconductor (CMOS), bipolar technologies like emitter-coupled logic (ECL), polymer technologies (e.g., silicon-conjugated polymer and metal-conjugated polymer-metal structures), mixed analog and digital, and/or the like.
The memory (126) may include a database (not shown) and may be, for example, a random access memory (RAM), a memory buffer, a hard drive, an erasable programmable read-only memory (EPROM), an electrically erasable read-only memory (EEPROM), a read-only memory (ROM), Flash memory, etc. The memory (126) may store instructions to cause the processor (124) to execute modules, processes and/or functions associated with the system (100), such as pulse waveform generation and/or cardiac pacing.
The apparatus (120) may be coupled to an ablation device (110) and/or a pacing device (130). When coupled to the ablation device (110) and pacing device (130), one or more components of the apparatus (120) (e.g., a processor (124) functioning as a signal generator (122) and/or cardiac stimulator (128)) can be in electrical communication with the ablation device (110) and/or pacing device (130) to control delivery of pacing signals, ablation signals, etc. via the ablation device (110) and pacing device (130) and/or to receive data (e.g., sensed signals) from the ablation device (110) and pacing device (130). If apparatus (120) includes multiple processors (124), one or more of the processor(s) (124) can communicate with one another to control pacing and/or ablation. The apparatus (120) can also include an input/output device (127) that enables the apparatus (120) to interface with other devices (e.g., ablation device (110) and/or pacing device (130)) and/or a user. For example, the apparatus (120) can include a user interface, e.g., a display, an audio device, etc. that enables presentation of outputs to a user and/or receipt of input from the user.
The signal generator (122) may be configured to generate ablation pulse waveforms for irreversible electroporation of tissue, such as, for example, pulmonary vein ostia. For example, the signal generator (122) may be a voltage pulse waveform generator and deliver a pulse waveform to the ablation device (110). The processor (124) may incorporate data received from memory (126), cardiac stimulator (128), and pacing device (130) to determine the parameters (e.g., timing, amplitude, width, duty cycle, etc.) of the pulse waveform to be generated by the signal generator (122). The memory (126) may further store instructions to cause the signal generator (122) to execute modules, processes and/or functions associated with the system (100), such as ectopic cardiac activity detection, pulse waveform generation, and/or cardiac pacing synchronization. For example, the memory (126) may be configured to store one or more of cardiac activity data, pulse waveform, and heart pacing data.
The pacing device (130) disposed in the patient may be configured to receive a heart pacing signal generated by the cardiac stimulator (128) of the apparatus (120) for cardiac stimulation. An indication of the pacing signal may be transmitted by the cardiac stimulator (128) to the signal generator (122). Based on the pacing signal, an indication of a voltage pulse waveform may be selected, computed, and/or otherwise identified by the processor (124) and generated by the signal generator (122). In some embodiments, the signal generator (122) is configured to generate the pulse waveform based on a cardiac activity status where the pulse waveform is in synchronization with the indication of the pacing signal (e.g., within a common refractory window). For example, in some embodiments, the common refractory window may start substantially immediately following a ventricular pacing signal (or after a very small delay) and last for a duration of approximately 250 milliseconds (ms) or less thereafter. In such embodiments, an entire pulse waveform may be delivered within this duration.
In some embodiments, one or more intracardiac electrodes, e.g., of the pacing device (130) and/or ablation device (110), can be configured to sense signals within the heart and deliver those signals to one or more of the processor(s) 124. The one or more processor(s) 124 can analyze the sensed signals for ectopic activity and control operation of the signal generator (122) based on such analysis, as further described below.
The system (100) may be in communication with other devices (not shown) via, for example, one or more networks, each of which may be any type of network. A wireless network may refer to any type of digital network that is not connected by cables of any kind. However, a wireless network may connect to a wireline network in order to interface with the Internet, other carrier voice and data networks, business networks, and personal networks. A wireline network is typically carried over copper twisted pair, coaxial cable or fiber optic cables. There are many different types of wireline networks including, wide area networks (WAN), metropolitan area networks (MAN), local area networks (LAN), campus area networks (CAN), global area networks (GAN), like the Internet, and virtual private networks (VPN). Hereinafter, network refers to any combination of combined wireless, wireline, public and private data networks that are typically interconnected through the Internet, to provide a unified networking and information access solution. The system (100) may further comprise one or more output devices such as a display, audio device, touchscreen, combinations thereof, and the like.
The ablation device (220) may be introduced into an endocardial space of the left atrium (204) through an atrial septum via a trans-septal puncture. The distal portion of the ablation device (220) may include a set of electrodes (222, 224) configured to deliver ablation energy (e.g., pulse electric field energy) to tissue. In some embodiments, the electrodes (222, 224) of the ablation device (220) may be a set of independently addressable electrodes. Each electrode may include an insulated electrical lead configured to sustain a voltage potential of at least about 700 V without dielectric breakdown of its corresponding insulation. In some embodiments, the insulation on each of the electrical leads may sustain an electrical potential difference of between about 200 V to about 2,500 V across its thickness without dielectric breakdown. In some embodiments, the set of electrodes may include a plurality of electrodes. The plurality of electrodes may be grouped into one or more anode-cathode subsets such as, for example, a subset including one anode and one cathode, a subset including two anodes and two cathodes, a subset including two anodes and one cathode, a subset including one anode and two cathodes, a subset including three anodes and one cathode, a subset including three anodes and two cathodes, and/or the like. While two electrodes (222, 224) are depicted, it can be appreciated that ablation device (220) can include one or more additional electrodes, where one or more sets of electrodes can be configured with opposite polarities to deliver pulsed electric fields to ablate tissue.
The operation of systems and devices for detection of pacing signals and/or ectopic activity can be understood with reference to
The controller (908) can be configured to generate a pacing stimulus and send that pacing stimulus to an intracardiac pacing catheter or similar medical device (e.g., pacing device (130)) via pacing output (920). The controller (908) can further send an indication (915) of the pacing stimulus to the controller (907), such that the delivery of the pulsed electric field energy can be synchronized with the cardiac pacing. The controllers (907, 908) can be operatively coupled to one another, e.g., by a communication bus (917). By synchronizing the delivery of the pulsed electric field ablation energy to the pacing stimulus, the apparatus (903) can ensure that pulsed electric field energy is delivery to sensitive anatomical structures (e.g., a cardiac chamber) during a refractory period, as described above, thereby avoiding the risk of inducing an arrhythmia such as a fibrillation event.
In some instances, an ectopic beat can arise by autonomous generation from a cardiac chamber. As described above, pulsed electric field ablation delivered during periods of ectopic activity can increase the risk of inducing an arrhythmia. Accordingly, it can be desirable to detect such ectopic activity. To detect such activity, cardiac signals (e.g., ECG recordings) from an intracardiac electrode pair can be sent as sensing signals (922) to the controller (908). The controller (908) can be configured to analyze the cardiac signals for ectopic beats. When the controller (908) detects an ectopic beat, the controller (908) can be configured to communicate with the controller (907) responsible for generating the ablation waveform, e.g., via communication bus (917), to halt the delivery of the pulsed electric field energy. For example, the controller (908) can send a signal to halt or interrupt ablation to the controller (907) in response to detecting ectopic activity.
In some embodiments, the apparatus (903) can be configured to confirm pacing capture prior to delivery of pulsed electric field energy. For example, the apparatus (903) via controller (908) can analyze the sensed cardiac signals (922) and communicate with controller (907) to deliver ablation upon confirmation of pacing capture. In some embodiments, the apparatus (903) can be equipped with a user interface for confirming pacing capture, e.g., via a manual input (927) by a user. For example, the apparatus (903) can include a display that displays the pacing signal and cardiac signal to allow a user to confirm pacing capture and indicate such confirmation to the apparatus (903) (e.g., by pushing a button on the user interface). In some embodiments, the apparatus (903) can analyze the sensed cardiac activity, and if such is found to not be in synchrony with the pacing stimulus, not perform ablation delivery and/or inform a user that pacing capture is absent (e.g., via user interface or a message). The user and/or apparatus (903) can then modify the pacing conditions, e.g., attempt pacing capture at a different rate, or move the pacing catheter to a location or position with better anatomical engagement.
In some embodiments, the analysis can be based on comparing data to one or more threshold values, e.g., predetermined and preprogrammed into the processor (1013) and/or provided by a user via a user input (1017) to a user interface (e.g., a touchscreen monitor or other type of monitor, etc.). Based on the analysis, the processor (1013) may be configured to output a cardiac activity status to a controller for generating an ablation waveform or pulse generator controller (e.g., the signal generator (122) or the controller (907)).
The signal (1015) may indicate one or more of pacing capture status (e.g., ECG signal in/out of synchrony with a pacing pulse) and ectopic cardiac activity status. For example, if pacing capture is not detected, the processor (1013) can send a corresponding status signal (1015) indicating a lack of pacing capture to a pulse generator controller. The processor (1013) and/or the pulse generator controller can then alert a user, e.g., through a user interface, that pacing capture is not present and ablation cannot be performed. The user can then take appropriate action such as, for example, halting an ablation procedure and/or reconfiguring the system. For example, the user may reposition one or more of an ablation device (e.g., ablation device (110)) and/or pacing device (e.g., pacing device (130)), and/or adjust other system parameters. If pacing capture is confirmed by the processor (1013), a different signal (1015) indicating readiness for ablation can be sent to the pulse generator controller, whereupon the pulse generator controller may be configured to initiate ablation when requested by a user. In some embodiments, systems and devices described herein may measure cardiac activity before, during, and after ablation energy delivery.
Additionally or alternatively, the processor (1013) can detect ectopic beats. For example, if pacing capture is confirmed but an ectopic beat is detected, the processor (1013) can be configured to send a signal (1015) to the pulse generator controller such that the pulse generator controller does not generate a pulse waveform for ablation. The processor (1013) and/or pulse generator controller can inform a user to the presence of ectopic beats and that ablation cannot be performed, e.g., via a user interface. The processor (1013) can also continue to monitor the sensed ECG signal for ectopic beats that may occur during ablation. If such ectopic beats are detected, the processor (1013) can send a signal (1015) to the pulse generator controller indicating that ablation should be paused or interrupted. The pulse generate controller, in response to receiving the signal (1015) can then half further ablation delivery, e.g., until the user adjusts the system and/or no ectopic beat activity is detected.
Also described here are methods for detecting ectopic cardiac activity during a tissue ablation process performed in a heart chamber using the systems and devices described above. The heart chamber may be the left atrial chamber and include its associated pulmonary veins. Generally, the methods described here include introducing and disposing a pacing device (e.g., pacing device (130), pacing device (210)) in contact with one or more heart chambers. The pacing device may measure cardiac activity and deliver a pacing signal to the heart using a cardiac stimulator or other processor (e.g., cardiac stimulator (128), controller (908), processor (1013)). The measured signals may be processed and analyzed to detect pacing capture and/or ectopic cardiac activity that may interfere with tissue ablation, e.g., by such processor and controllers as described herein. An ablation device (e.g., ablation device (110), ablation device (220)) may be introduced and disposed in contact with one or more pulmonary vein ostial or antral regions. A pulse waveform may be delivered by one or more electrodes (e.g., electrodes (112), electrodes (222, 224)) of the ablation device to ablate tissue. In some embodiments, detection of autonomously generated ectopic cardiac activity may drive prompt interruption of ablation energy delivery, thereby reducing the risk of inducing an arrhythmia (e.g., fibrillation). Furthermore, a cardiac pacing signal (e.g., delivered by a pacing device (e.g., pacing device (130), pacing device (210)) may synchronize the delivered pulse waveforms with the cardiac cycle. By synchronizing the delivery of ablation energy to a pacing stimulus (e.g., during a refractory period), the risk of inducing an arrhythmia such as fibrillation may be further reduced.
Additionally or alternatively, the pulse waveforms may include a plurality of levels of a hierarchy to reduce total energy delivery, e.g., as described in International Application Serial No. PCT/US2019/031135, filed on May 7, 2019, and titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE,” the contents of which are hereby incorporated by reference in its entirety. The tissue ablation thus performed may be delivered in the absence of ectopic cardiac activity and in synchrony with paced heartbeats to reduce the risk of atrial and/or ventricular fibrillation and damage to healthy tissue. It should be appreciated that any of the ablation devices described herein (e.g., ablation device (110), ablation device (220)) may be used to ablate tissue using the methods discussed below as appropriate.
In some embodiments, the ablation devices described herein (e.g., ablation device (110), ablation device (220)) may be used for epicardial and/or endocardial ablation. Examples of suitable ablation catheters are described in International Application Serial No. PCT/US2019/014226.
An apparatus (e.g., apparatus (120, 903)) can process and/or analyze the cardiac signal sensed by the one or more electrodes. Based on analysis of the cardiac data, a status signal may be generated, at (416). The status signal may indicate a status of one or more of pacing capture and/or ectopic cardiac activity. For example,
In some embodiments, pacing capture may be automatically confirmed by apparatuses described herein (e.g., apparatus (120, 903)) based on the received cardiac data. Additionally or alternatively, pacing capture may be confirmed by a user, e.g., after viewing an output of the pacing signal and cardiac signal data. For example, the user may confirm pacing capture using a user interface (e.g., an input/output device such as a touch screen monitor or other type of monitor) based on a cardiac activity output on a display. If the signal generator and/or processor, or the user viewing the displayed cardiac output, determines that there is one or more of ectopic cardiac activity and an absence of pacing capture, pulse waveform generation may be prohibited and the user may be prompted to adjust system parameters by, for example, repositioning the pacing device to improve tissue engagement and/or modify pacing signal parameters (e.g., pulse width, pulse amplitude, pulse frequency, etc.).
The generated pulse waveform may be delivered to tissue, at (422). In some embodiments, a voltage pulse waveform may be applied in a common refractory time period associated with atrial and ventricular pacing signals. Depending on the cardiac data that is captured and/or other parameters associated ablation delivery, the pulse waveform may be generated with a time offset with respect to the indication of the pacing signal. For example, the refractory time period may be offset from the pacing signal by predetermined time period, and the ablation device can be configured to deliver the pulses during the refractory time period that is offset from the pacing signal. In some embodiment, the voltage pulse waveform(s) may be applied over a series of heartbeats over corresponding refractory time periods (e.g., common refractory periods).
In some embodiments, the pulse waveform may be delivered to pulmonary vein ostium of a heart of a patient via one or more splines of a set of splines of an ablation device (e.g., ablation device (110, 220). In other embodiments, voltage pulse waveforms as described herein may be selectively delivered to electrode subsets such as anode-cathode subsets for ablation and isolation of the pulmonary vein. For example, a first electrode of a group of electrodes may be configured as an anode and a second electrode of the group of electrodes may be configured as a cathode. These steps may be repeated for a desired number of pulmonary vein ostial or antral regions to have been ablated (e.g., 1, 2, 3, or 4 ostia). Suitable examples of ablation devices and methods are described in International Application No. PCT/US2019/014226.
The processed cardiac activity data may be analyzed for one or more of ectopic cardiac activity and pacing capture, at (508). For example, the processed cardiac activity data can be analyzed by extracting sliding windows of the data, and each sliding window can be evaluated for ectopic cardiac activity, e.g., using discrete Fourier transform methods. Specific implementations of such analysis are further described with reference to
In some embodiments, ectopic cardiac activity detection, at (510), may be performed in parallel with pacing capture detection, at (512). In other embodiments, pacing capture detection, at (512), can be performed prior to performing ectopic cardiac activity detection, at (510).
A status signal may be generated, at (514), based on the results of the detected ectopic cardiac activity and/or pacing capture. In some embodiments, the status signal may be output to one or more components of an ablation apparatus (e.g., apparatus (120)), including, for example, a signal or pulse generator (e.g., signal generator (122)) and/or another compute device. For example, a user interface (e.g., a user interface such as a display, including in an apparatus (120)) of a tissue ablation system may be configured to display an indication confirming pacing capture (e.g., “Pacing Capture Confirmed”) and display an “Ablation” icon configured to allow a user to initiate delivery of ablation energy to tissue. In some embodiments, the cardiac activity status need not be output to a user if pacing capture is confirmed and no ectopic beat is detected. Rather, an indication (e.g., an audio and/or visual alarm) can be made when either pacing capture cannot be confirmed or when an ectopic beat is detected.
At (710), the buffered data may be analyzed by extracting sliding windows of predetermined length. For example, beginning at a time interval equal to the pacing pulse width after the leading edge of the pacing pulse, the buffered data is extracted in sliding windows of a predetermined length (e.g., a window of 220 data points), which corresponds to a frequency resolution of approximately 4.54 Hz. The sliding window can start after the pacing pulse (i.e., after a time interval equal to the pulse width), and be advanced in discrete steps, e.g., with a step size equal to a preset number of sampling time intervals such as 10 sampling time intervals. The number of sliding windows extracted from the buffered data per cardiac cycle may depend on one or more parameters, such as, for example, a length between pacing pulses, window length, and/or step size, each of which can be a predetermined parameter.
A discrete Fourier Transform (e.g., Fast Fourier Transform) may be performed for each sliding window, at (712). The result of the Fourier Transform (e.g., amplitude) may be filtered (e.g., by a smoothing filter) to output a function ƒ corresponding to a local average over a set of neighboring values around each data point, at (714). Local peaks in function ƒ may be identified over a subrange of the data of each sliding window. For example, if a sliding window had a length of 220 data points, a subrange ranging from about 12 to about 100 (12th data point to 100th data point) can be used, which corresponds to a frequency band from about 54 Hz to about 454 Hz. While these specific sliding window lengths and frequency bands are provided as examples, it can be appreciated that other sliding window lengths and frequency bands can be used, e.g., depending on desired parameters, processing capability, etc. Analysis of peaks within the frequency band can be used to determine whether ectopic cardiac activity is present, at (720).
The processed ECG data within each sliding window can be used to detect ectopic cardiac activity. In an embodiment, an ectopic beat may be detected based on a comparison between a ratio of a peak value (ap) of ƒ over the predetermined interval (or subrange or frequency band) to the maximum value (amax) of ƒ up to the Nyquist frequency to a predetermined threshold t. In some embodiments, an ectopic beat may be detected in the sliding window when the ratio ap/amax is greater than t. Because ectopic beats increase the amount of certain frequencies in ECG signals, detection can be accomplished by identifying instances where a greater than normal amount of a frequency is present in the sampled cardiac data. In some embodiments, t may be between about 0.01 and about 0.25, between about 0.01 and about 0.2, between about 0.01 and about 0.15, including all sub-values and ranges in-between. In some embodiments, the user may input t into a user interface of a tissue ablation system, at (716). The threshold t can represent a sensitivity of the system, i.e., a system with a lower threshold t would have greater sensitivity than a system with higher threshold t.
When an ectopic beat is not detected in a particular sliding window (720: NO), the process continues onto the next sliding window. When an ectopic beat is detected (720: YES), then a status signal can be generated, at (724), e.g., that notifies a compute device and/or a user of the ectopic activity, as described above with reference to (514) in
In some embodiments, received ECG data can be used to confirm pacing capture. For example, as depicted in
At (810), the buffered data may be analyzed by extracting sliding windows of the data, each sliding window having a predetermined length and being advanced in discrete steps through the buffered data. Detection of ectopic beats, e.g., via a discrete Fourier Transform of the data, at (812), filtering and analysis of the data, at (814), and detection of peaks in the Fourier Transform data that is greater than a preset threshold, at (820), can be similar to that described in
With ECG data being available, pacing capture can also be confirmed, at (822). To confirm pacing capture, a subset of sampled data can be extracted from the ECG data at the start of the pacing signal, as indicated by (837). For example, ECG data associated with a predetermined time interval T (e.g., a pacing pulse duration) starting from onset of a pacing pulse can be extracted. For example, the time period may have a length of between about 5 ms and about 50 ms. Accordingly, the subset of sampled data can, for example, include the first ten to fifty data points, depending on the sampling frequency and time interval T A function g(t) may be defined by the subset of sampled data over the time interval T. In some embodiments, g(t) may represent an ECG signal scaled with respect to a maximum magnitude of the ECG signal over the time interval T. A set of moments (e.g., M0, M1, . . . , Mn) of this function over the time interval T may be calculated, and can be tracked over a predetermined number of successive pacing periods (e.g., 1, 2, 3, 4, 5 successive pacing periods). The set of moments of the function can include, for example, the first three moments, which can be computed in discretized form as average values, or as other suitable integral representations (e.g., using the trapezoidal rule, Simpson's rule, or other integral measures) of g(t), tg(t), and t2g(t) over the time interval T.
With the calculated moments, an average value An of the nth moment over a set of i successive periods may be given by: An=(Mn1+Mn2+Mn3+ . . . +Mni)/i. Accordingly, for the first three moments over 5 successive pacing periods, the average values will be:
A0=(M01+M02+ . . . M05)/5
A1=(M11+M12+ . . . M15)/5
A2=(M21+M22+ . . . M25)/5
A normalized difference between the average moment value An and the moment value for the ith time period (e.g., for five time periods, i=1, 2, . . . , 5) of a given moment n may be calculated. For the first three moments (n=1, 2, 3), the following set of equations provide this normalized difference:
Si=|A0−M0i|/A0
Ti=|A1−M1i|/A1
Ui=|A2−M2i|/A2
where the Si, Ti, and Ui values are set to zero when the corresponding one of A0, A1, or A2 are zero.
Confirmation of pacing capture may be detected based on the Si, Ti, and Ui values. For example, pacing capture over i predetermined time periods can be confirmed if for each non-zero value of An, its corresponding Si, Ti, or Ui value is less than a predetermined threshold or set of threshold values. For example, this threshold for the moment M0 can be in the range between 0 and 0.1. A small deviation of the moment Mni from the corresponding mean value indicates that the time-behavior of the ECG signal (viewed as a function of time) is morphologically consistent over successive pacing periods, thereby demonstrating pacing capture. In some embodiments, this threshold can be defined by a user, e.g., via input (816) provided by a user interface (e.g., of input/output device (127)). If pacing capture is confirmed (822), then this can be indicated, e.g., on a user interface by highlighting a “Pacing Capture Confirmed” indicator.
As described above with reference to
In some embodiments, hierarchical voltage pulse waveforms having a nested structure and a hierarchy of time intervals as described herein may be useful for irreversible electroporation, providing control and selectivity in different tissue types.
A pulse waveform may be generated by a signal generator (e.g., signal generator (122)) and may include a plurality of levels in a hierarchy, at (610). A variety of hierarchical waveforms may be generated with a signal generator as disclosed herein. For example, the pulse waveform may include a first level of a hierarchy of the pulse waveform including a first set of pulses. Each pulse has a pulse time duration and a first time interval separating successive pulses. A second level of the hierarchy of the pulse waveform may include a plurality of first sets of pulses as a second set of pulses. A second time interval may separate successive first sets of pulses. The second time interval may be at least three times the duration of the first time interval. A third level of the hierarchy of the pulse waveform may include a plurality of second sets of pulses as a third set of pulses. A third time interval may separate successive second sets of pulses. The third time interval may be at least thirty times the duration of the second level time interval. The pulse waveform generated by the signal generator may be delivered to tissue using the ablation device, at (612). As described herein, if ectopic beat activity is detected or pacing capture is not confirmed, then the delivery of pulse waveform activity may be interrupted, e.g., at (608) or (610). Examples of pulse waveforms that can be used with the ablation devices described herein are provided in International Application No. PCT/US2016/57664, filed on Oct. 19, 2016, titled “Systems, apparatuses and methods for delivery of ablative energy to tissue,” incorporated herein by reference in its entirety.
It is understood that while the examples herein identify separate monophasic and biphasic waveforms, it should be appreciated that combination waveforms, where some portions of the waveform hierarchy are monophasic while other portions are biphasic, may also be generated. A voltage pulse waveform having a hierarchical structure may be applied across different anode-cathode subsets (optionally with a time delay). As discussed above, one or more of the waveforms applied across the anode-cathode subsets may be applied during the refractory period of a cardiac cycle. The pulse waveform may be delivered to tissue. It should be appreciated that the steps described in certain figures may be combined and modified as appropriate.
It should be understood that the examples and illustrations in this disclosure serve exemplary purposes and departures and variations such as numbers of splines, number of electrodes, and so on can be built and deployed according to the teachings herein without departing from the scope of this invention. While specific parameters such as sampling frequency, time intervals and so on were given for exemplary purposes only in the description herein, it should be understood that other values of the various parameters can be used as convenient for the application by those skilled in the art based on the teachings presented in this disclosure.
As used herein, the terms “about” and/or “approximately” when used in conjunction with numerical values and/or ranges generally refer to those numerical values and/or ranges near to a recited numerical value and/or range. In some instances, the terms “about” and “approximately” may mean within ±10% of the recited value. For example, in some instances, “about 100 [units]” may mean within ±10% of 100 (e.g., from 90 to 110). The terms “about” and “approximately” may be used interchangeably.
Some embodiments described herein relate to a computer storage product with a non-transitory computer-readable medium (also may be referred to as a non-transitory processor-readable medium) having instructions or computer code thereon for performing various computer-implemented operations. The computer-readable medium (or processor-readable medium) is non-transitory in the sense that it does not include transitory propagating signals per se (e.g., a propagating electromagnetic wave carrying information on a transmission medium such as space or a cable). The media and computer code (also may be referred to as code or algorithm) may be those designed and constructed for the specific purpose or purposes. Examples of non-transitory computer-readable media include, but are not limited to, magnetic storage media such as hard disks, floppy disks, and magnetic tape; optical storage media such as Compact Disc/Digital Video Discs (CD/DVDs), Compact Disc-Read Only Memories (CD-ROMs), and holographic devices; magneto-optical storage media such as optical disks; carrier wave signal processing modules; and hardware devices that are specially configured to store and execute program code, such as Application-Specific Integrated Circuits (ASICs), Programmable Logic Devices (PLDs), Read-Only Memory (ROM) and Random-Access Memory (RAM) devices. Other embodiments described herein relate to a computer program product, which may include, for example, the instructions and/or computer code disclosed herein.
The systems, devices, and/or methods described herein may be performed by software (executed on hardware), hardware, or a combination thereof. Hardware modules may include, for example, a general-purpose processor (or microprocessor or microcontroller), a field programmable gate array (FPGA), and/or an application specific integrated circuit (ASIC). Software modules (executed on hardware) may be expressed in a variety of software languages (e.g., computer code), including C, C++, Java®, Ruby, Visual Basic®, and/or other object-oriented, procedural, or other programming language and development tools. Examples of computer code include, but are not limited to, micro-code or micro-instructions, machine instructions, such as produced by a compiler, code used to produce a web service, and files containing higher-level instructions that are executed by a computer using an interpreter. Additional examples of computer code include, but are not limited to, control signals, encrypted code, and compressed code.
The specific examples and descriptions herein are exemplary in nature and embodiments may be developed by those skilled in the art based on the material taught herein without departing from the scope of the present invention.
This application is a continuation of U.S. patent application Ser. No. 16/573,704, filed on Sep. 17, 2019, now issued as U.S. Pat. No. 10,625,080, the entire disclosure of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4200104 | Harris | Apr 1980 | A |
4438766 | Bowers | Mar 1984 | A |
4470407 | Hussein | Sep 1984 | A |
4739759 | Rexroth et al. | Apr 1988 | A |
5234004 | Hascoet et al. | Aug 1993 | A |
5242441 | Avitall | Sep 1993 | A |
5257635 | Langberg | Nov 1993 | A |
5281213 | Milder et al. | Jan 1994 | A |
5304214 | DeFord et al. | Apr 1994 | A |
5306296 | Wright et al. | Apr 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5342301 | Saab | Aug 1994 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5443463 | Stern et al. | Aug 1995 | A |
5454370 | Avitall | Oct 1995 | A |
5515848 | Corbett, III et al. | May 1996 | A |
5531685 | Hemmer et al. | Jul 1996 | A |
5545161 | Imran | Aug 1996 | A |
5558091 | Acker et al. | Sep 1996 | A |
5578040 | Smith | Nov 1996 | A |
5617854 | Munsif | Apr 1997 | A |
5624430 | Eton et al. | Apr 1997 | A |
5662108 | Budd et al. | Sep 1997 | A |
5667491 | Pliquett et al. | Sep 1997 | A |
5672170 | Cho | Sep 1997 | A |
5700243 | Narciso, Jr. | Dec 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5706823 | Wodlinger | Jan 1998 | A |
5722400 | Ockuly et al. | Mar 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5749914 | Janssen | May 1998 | A |
5779699 | Lipson | Jul 1998 | A |
5788692 | Campbell et al. | Aug 1998 | A |
5810762 | Hofmann | Sep 1998 | A |
5833710 | Jacobson | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5836942 | Netherly et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5843154 | Osypka | Dec 1998 | A |
5849028 | Chen | Dec 1998 | A |
5863291 | Schaer | Jan 1999 | A |
5868736 | Swanson et al. | Feb 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5876336 | Swanson et al. | Mar 1999 | A |
5885278 | Fleischman et al. | Mar 1999 | A |
5895404 | Ruiz | Apr 1999 | A |
5899917 | Edwards et al. | May 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5916158 | Webster, Jr. | Jun 1999 | A |
5916213 | Haissaguerre et al. | Jun 1999 | A |
5921924 | Avitall | Jul 1999 | A |
5928269 | Alt | Jul 1999 | A |
5928270 | Ramsey, III | Jul 1999 | A |
6002955 | Willems et al. | Dec 1999 | A |
6006131 | Cooper et al. | Dec 1999 | A |
6009351 | Flachman | Dec 1999 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6033403 | Tu et al. | Mar 2000 | A |
6035238 | Ingle et al. | Mar 2000 | A |
6045550 | Simpson et al. | Apr 2000 | A |
6068653 | LaFontaine | May 2000 | A |
6071274 | Thompson et al. | Jun 2000 | A |
6071281 | Burnside et al. | Jun 2000 | A |
6074389 | Levine et al. | Jun 2000 | A |
6076012 | Swanson et al. | Jun 2000 | A |
6090104 | Webster, Jr. | Jul 2000 | A |
6096036 | Bowe et al. | Aug 2000 | A |
6113595 | Muntermann | Sep 2000 | A |
6119041 | Pomeranz et al. | Sep 2000 | A |
6120500 | Bednarek et al. | Sep 2000 | A |
6146381 | Bowe et al. | Nov 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6167291 | Barajas et al. | Dec 2000 | A |
6171305 | Sherman | Jan 2001 | B1 |
6216034 | Hofmann et al. | Apr 2001 | B1 |
6219582 | Hofstad et al. | Apr 2001 | B1 |
6223085 | Dann et al. | Apr 2001 | B1 |
6231518 | Grabek et al. | May 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6251107 | Schaer | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6270476 | Santoianni et al. | Aug 2001 | B1 |
6272384 | Simon et al. | Aug 2001 | B1 |
6287306 | Kroll et al. | Sep 2001 | B1 |
6314963 | Vaska et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6350263 | Wetzig et al. | Feb 2002 | B1 |
6370412 | Armoundas et al. | Apr 2002 | B1 |
6391024 | Sun et al. | May 2002 | B1 |
6447505 | McGovern et al. | Sep 2002 | B2 |
6464699 | Swanson | Oct 2002 | B1 |
6470211 | Ideker et al. | Oct 2002 | B1 |
6502576 | Lesh | Jan 2003 | B1 |
6503247 | Swartz et al. | Jan 2003 | B2 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6527724 | Fenici | Mar 2003 | B1 |
6527767 | Wang et al. | Mar 2003 | B2 |
6592581 | Bowe | Jul 2003 | B2 |
6595991 | Tollner et al. | Jul 2003 | B2 |
6607520 | Keane | Aug 2003 | B2 |
6623480 | Kuo et al. | Sep 2003 | B1 |
6638278 | Falwell et al. | Oct 2003 | B2 |
6666863 | Wentzel et al. | Dec 2003 | B2 |
6669693 | Friedman | Dec 2003 | B2 |
6702811 | Stewart et al. | Mar 2004 | B2 |
6719756 | Muntermann | Apr 2004 | B1 |
6723092 | Brown et al. | Apr 2004 | B2 |
6728563 | Rashidi | Apr 2004 | B2 |
6743225 | Sanchez et al. | Jun 2004 | B2 |
6743226 | Cosman et al. | Jun 2004 | B2 |
6743239 | Kuehn et al. | Jun 2004 | B1 |
6764486 | Natale | Jul 2004 | B2 |
6780181 | Kroll et al. | Aug 2004 | B2 |
6805128 | Pless | Oct 2004 | B1 |
6807447 | Griffin, III | Oct 2004 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
6893438 | Hall et al. | May 2005 | B2 |
6926714 | Sra | Aug 2005 | B1 |
6955173 | Lesh | Oct 2005 | B2 |
6960206 | Keane | Nov 2005 | B2 |
6960207 | Vanney et al. | Nov 2005 | B2 |
6972016 | Hill, III et al. | Dec 2005 | B2 |
6973339 | Govari | Dec 2005 | B2 |
6979331 | Hintringer et al. | Dec 2005 | B2 |
6984232 | Vanney et al. | Jan 2006 | B2 |
6985776 | Kane et al. | Jan 2006 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7041095 | Wang et al. | May 2006 | B2 |
7113831 | Hooven | Sep 2006 | B2 |
7171263 | Darvish et al. | Jan 2007 | B2 |
7182725 | Bonan et al. | Feb 2007 | B2 |
7195628 | Falkenberg | Mar 2007 | B2 |
7207988 | Leckrone et al. | Apr 2007 | B2 |
7207989 | Pike, Jr. et al. | Apr 2007 | B2 |
7229402 | Diaz et al. | Jun 2007 | B2 |
7229437 | Johnson et al. | Jun 2007 | B2 |
7250049 | Roop et al. | Jul 2007 | B2 |
7285116 | de la Rama et al. | Oct 2007 | B2 |
7285119 | Stewart et al. | Oct 2007 | B2 |
7326208 | Vanney et al. | Feb 2008 | B2 |
7346379 | Eng et al. | Mar 2008 | B2 |
7367974 | Haemmerich et al. | May 2008 | B2 |
7374567 | Heuser | May 2008 | B2 |
7387629 | Vanney et al. | Jun 2008 | B2 |
7387630 | Mest | Jun 2008 | B2 |
7387636 | Cohn et al. | Jun 2008 | B2 |
7416552 | Paul et al. | Aug 2008 | B2 |
7419477 | Simpson et al. | Sep 2008 | B2 |
7419489 | Vanney et al. | Sep 2008 | B2 |
7422591 | Phan | Sep 2008 | B2 |
7429261 | Kunis et al. | Sep 2008 | B2 |
7435248 | Taimisto et al. | Oct 2008 | B2 |
7513896 | Orszulak | Apr 2009 | B2 |
7527625 | Knight et al. | May 2009 | B2 |
7578816 | Boveja et al. | Aug 2009 | B2 |
7588567 | Boveja et al. | Sep 2009 | B2 |
7623899 | Worley et al. | Nov 2009 | B2 |
7678108 | Chrisitian et al. | Mar 2010 | B2 |
7681579 | Schwartz | Mar 2010 | B2 |
7771421 | Stewart et al. | Aug 2010 | B2 |
7805182 | Weese et al. | Sep 2010 | B2 |
7850642 | Moll et al. | Dec 2010 | B2 |
7850685 | Kunis et al. | Dec 2010 | B2 |
7857808 | Oral et al. | Dec 2010 | B2 |
7857809 | Drysen | Dec 2010 | B2 |
7869865 | Govari et al. | Jan 2011 | B2 |
7896873 | Hiller et al. | Mar 2011 | B2 |
7917211 | Zacouto | Mar 2011 | B2 |
7918819 | Karmarkar et al. | Apr 2011 | B2 |
7918850 | Govari et al. | Apr 2011 | B2 |
7922714 | Stevens-Wright | Apr 2011 | B2 |
7955827 | Rubinsky et al. | Jun 2011 | B2 |
8048067 | Davalos et al. | Nov 2011 | B2 |
8048072 | Verin et al. | Nov 2011 | B2 |
8100895 | Panos et al. | Jan 2012 | B2 |
8100900 | Prinz et al. | Jan 2012 | B2 |
8108069 | Stahler et al. | Jan 2012 | B2 |
8133220 | Lee et al. | Mar 2012 | B2 |
8137342 | Crossman | Mar 2012 | B2 |
8145289 | Calabro′ et al. | Mar 2012 | B2 |
8147486 | Honour et al. | Apr 2012 | B2 |
8160690 | Wilfley et al. | Apr 2012 | B2 |
8175680 | Panescu | May 2012 | B2 |
8182477 | Orszulak et al. | May 2012 | B2 |
8206384 | Falwell et al. | Jun 2012 | B2 |
8206385 | Stangenes et al. | Jun 2012 | B2 |
8216221 | Ibrahim et al. | Jul 2012 | B2 |
8221411 | Francischelli et al. | Jul 2012 | B2 |
8226648 | Paul et al. | Jul 2012 | B2 |
8228065 | Wirtz et al. | Jul 2012 | B2 |
8235986 | Kulesa et al. | Aug 2012 | B2 |
8235988 | Davis et al. | Aug 2012 | B2 |
8251986 | Chornenky et al. | Aug 2012 | B2 |
8282631 | Davalos et al. | Oct 2012 | B2 |
8287532 | Carroll et al. | Oct 2012 | B2 |
8414508 | Thapliyal et al. | Apr 2013 | B2 |
8430875 | Ibrahim et al. | Apr 2013 | B2 |
8433394 | Harlev et al. | Apr 2013 | B2 |
8449535 | Deno et al. | May 2013 | B2 |
8454594 | Demarais et al. | Jun 2013 | B2 |
8463368 | Harlev et al. | Jun 2013 | B2 |
8475450 | Govari et al. | Jul 2013 | B2 |
8486063 | Werneth et al. | Jul 2013 | B2 |
8500733 | Watson | Aug 2013 | B2 |
8535304 | Sklar et al. | Sep 2013 | B2 |
8538501 | Venkatachalam et al. | Sep 2013 | B2 |
8562588 | Hobbs et al. | Oct 2013 | B2 |
8568406 | Harlev et al. | Oct 2013 | B2 |
8571635 | McGee | Oct 2013 | B2 |
8571647 | Harlev et al. | Oct 2013 | B2 |
8585695 | Shih | Nov 2013 | B2 |
8588885 | Hall et al. | Nov 2013 | B2 |
8597288 | Christian | Dec 2013 | B2 |
8608735 | Govari et al. | Dec 2013 | B2 |
8628522 | Ibrahim et al. | Jan 2014 | B2 |
8632534 | Pearson et al. | Jan 2014 | B2 |
8647338 | Chornenky et al. | Feb 2014 | B2 |
8708952 | Cohen et al. | Apr 2014 | B2 |
8734442 | Cao et al. | May 2014 | B2 |
8771267 | Kunis et al. | Jul 2014 | B2 |
8795310 | Fung et al. | Aug 2014 | B2 |
8808273 | Caples et al. | Aug 2014 | B2 |
8808281 | Emons et al. | Aug 2014 | B2 |
8834461 | Werneth et al. | Sep 2014 | B2 |
8834464 | Stewart et al. | Sep 2014 | B2 |
8868169 | Narayan et al. | Oct 2014 | B2 |
8876817 | Avitall et al. | Nov 2014 | B2 |
8880195 | Azure | Nov 2014 | B2 |
8886309 | Luther et al. | Nov 2014 | B2 |
8903488 | Callas et al. | Dec 2014 | B2 |
8920411 | Gelbart et al. | Dec 2014 | B2 |
8926589 | Govari | Jan 2015 | B2 |
8932287 | Gelbart et al. | Jan 2015 | B2 |
8945117 | Bencini | Feb 2015 | B2 |
8979841 | Kunis et al. | Mar 2015 | B2 |
8986278 | Fung et al. | Mar 2015 | B2 |
9002442 | Harley et al. | Apr 2015 | B2 |
9005189 | Davalos et al. | Apr 2015 | B2 |
9005194 | Oral et al. | Apr 2015 | B2 |
9011425 | Fischer et al. | Apr 2015 | B2 |
9044245 | Condie et al. | Jun 2015 | B2 |
9055959 | Vaska et al. | Jun 2015 | B2 |
9072518 | Swanson | Jul 2015 | B2 |
9078667 | Besser et al. | Jul 2015 | B2 |
9101374 | Hoch et al. | Aug 2015 | B1 |
9119533 | Ghaffari | Sep 2015 | B2 |
9119634 | Gelbart et al. | Sep 2015 | B2 |
9131897 | Harada et al. | Sep 2015 | B2 |
9155590 | Mathur | Oct 2015 | B2 |
9162037 | Belson et al. | Oct 2015 | B2 |
9179972 | Olson | Nov 2015 | B2 |
9186481 | Avitall et al. | Nov 2015 | B2 |
9192769 | Donofrio et al. | Nov 2015 | B2 |
9211405 | Mahapatra et al. | Dec 2015 | B2 |
9216055 | Spence et al. | Dec 2015 | B2 |
9233248 | Luther et al. | Jan 2016 | B2 |
9237926 | Nollert et al. | Jan 2016 | B2 |
9262252 | Kirkpatrick et al. | Feb 2016 | B2 |
9277957 | Long et al. | Mar 2016 | B2 |
9282910 | Narayan et al. | Mar 2016 | B2 |
9289258 | Cohen | Mar 2016 | B2 |
9289606 | Paul et al. | Mar 2016 | B2 |
9295516 | Pearson et al. | Mar 2016 | B2 |
9301801 | Scheib | Apr 2016 | B2 |
9375268 | Long | Jun 2016 | B2 |
9414881 | Callas et al. | Aug 2016 | B2 |
9468495 | Kunis et al. | Oct 2016 | B2 |
9474486 | Eliason et al. | Oct 2016 | B2 |
9474574 | Ibrahim et al. | Oct 2016 | B2 |
9480525 | Lopes et al. | Nov 2016 | B2 |
9486272 | Bonyak et al. | Nov 2016 | B2 |
9486273 | Lopes et al. | Nov 2016 | B2 |
9492227 | Lopes et al. | Nov 2016 | B2 |
9492228 | Lopes et al. | Nov 2016 | B2 |
9517103 | Panescu et al. | Dec 2016 | B2 |
9526573 | Lopes et al. | Dec 2016 | B2 |
9532831 | Reinders et al. | Jan 2017 | B2 |
9539010 | Gagner et al. | Jan 2017 | B2 |
9554848 | Stewart et al. | Jan 2017 | B2 |
9554851 | Sklar et al. | Jan 2017 | B2 |
9700368 | Callas et al. | Jul 2017 | B2 |
9724170 | Mickelsen | Aug 2017 | B2 |
9757193 | Zarins et al. | Sep 2017 | B2 |
9782099 | Williams et al. | Oct 2017 | B2 |
9788885 | Long et al. | Oct 2017 | B2 |
9795442 | Salahieh et al. | Oct 2017 | B2 |
9861802 | Mickelsen | Jan 2018 | B2 |
9913685 | Clark et al. | Mar 2018 | B2 |
9931487 | Quinn et al. | Apr 2018 | B2 |
9987081 | Bowers et al. | Jun 2018 | B1 |
9999465 | Long et al. | Jun 2018 | B2 |
10016232 | Bowers et al. | Jul 2018 | B1 |
10117701 | Davalos et al. | Nov 2018 | B2 |
10117707 | Garcia et al. | Nov 2018 | B2 |
10130423 | Viswanathan et al. | Nov 2018 | B1 |
10172673 | Viswanathan et al. | Jan 2019 | B2 |
10292755 | Arena et al. | May 2019 | B2 |
10322286 | Viswanathan et al. | Jun 2019 | B2 |
10342598 | Long et al. | Jul 2019 | B2 |
10433906 | Mickelsen | Oct 2019 | B2 |
10433908 | Viswanathan et al. | Oct 2019 | B2 |
10448989 | Arena et al. | Oct 2019 | B2 |
10507302 | Leeflang et al. | Dec 2019 | B2 |
10512505 | Viswanathan | Dec 2019 | B2 |
10512779 | Viswanathan et al. | Dec 2019 | B2 |
10517672 | Long | Dec 2019 | B2 |
10531914 | Stewart et al. | Jan 2020 | B2 |
20010000791 | Suorsa et al. | May 2001 | A1 |
20010007070 | Stewart et al. | Jul 2001 | A1 |
20010044624 | Seraj et al. | Nov 2001 | A1 |
20020052602 | Wang et al. | May 2002 | A1 |
20020077627 | Johnson et al. | Jun 2002 | A1 |
20020087169 | Brock et al. | Jul 2002 | A1 |
20020091384 | Hooven et al. | Jul 2002 | A1 |
20020095176 | Liddicoat et al. | Jul 2002 | A1 |
20020111618 | Stewart et al. | Aug 2002 | A1 |
20020156526 | Hlavka et al. | Oct 2002 | A1 |
20020161323 | Miller et al. | Oct 2002 | A1 |
20020169445 | Jain et al. | Nov 2002 | A1 |
20020177765 | Bowe et al. | Nov 2002 | A1 |
20020183638 | Swanson | Dec 2002 | A1 |
20030014098 | Quijano et al. | Jan 2003 | A1 |
20030018374 | Paulos | Jan 2003 | A1 |
20030023287 | Edwards et al. | Jan 2003 | A1 |
20030028189 | Woloszko et al. | Feb 2003 | A1 |
20030050637 | Maguire et al. | Mar 2003 | A1 |
20030114849 | Ryan | Jun 2003 | A1 |
20030125729 | Hooven et al. | Jul 2003 | A1 |
20030130598 | Manning et al. | Jul 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030204161 | Ferek Petric | Oct 2003 | A1 |
20030229379 | Ramsey | Dec 2003 | A1 |
20040039382 | Kroll et al. | Feb 2004 | A1 |
20040049181 | Stewart et al. | Mar 2004 | A1 |
20040049182 | Koblish et al. | Mar 2004 | A1 |
20040082859 | Schaer | Apr 2004 | A1 |
20040082948 | Stewart et al. | Apr 2004 | A1 |
20040087939 | Eggers et al. | May 2004 | A1 |
20040111087 | Stern et al. | Jun 2004 | A1 |
20040199157 | Palanker et al. | Oct 2004 | A1 |
20040215139 | Cohen | Oct 2004 | A1 |
20040231683 | Eng et al. | Nov 2004 | A1 |
20040236360 | Cohn et al. | Nov 2004 | A1 |
20040254607 | Wittenberger et al. | Dec 2004 | A1 |
20040267337 | Hayzelden | Dec 2004 | A1 |
20050033282 | Hooven | Feb 2005 | A1 |
20050187545 | Hooven et al. | Aug 2005 | A1 |
20050222632 | Obino | Oct 2005 | A1 |
20050251130 | Boveja et al. | Nov 2005 | A1 |
20050261672 | Deem et al. | Nov 2005 | A1 |
20060009755 | Sra | Jan 2006 | A1 |
20060009759 | Chrisitian et al. | Jan 2006 | A1 |
20060015095 | Desinger et al. | Jan 2006 | A1 |
20060015165 | Bertolero et al. | Jan 2006 | A1 |
20060024359 | Walker et al. | Feb 2006 | A1 |
20060058781 | Long | Mar 2006 | A1 |
20060111702 | Oral et al. | May 2006 | A1 |
20060142801 | Demarais et al. | Jun 2006 | A1 |
20060167448 | Kozel | Jul 2006 | A1 |
20060217703 | Chornenky et al. | Sep 2006 | A1 |
20060241734 | Marshall et al. | Oct 2006 | A1 |
20060264752 | Rubinsky et al. | Nov 2006 | A1 |
20060270900 | Chin et al. | Nov 2006 | A1 |
20060287648 | Schwartz | Dec 2006 | A1 |
20060293730 | Rubinsky et al. | Dec 2006 | A1 |
20060293731 | Rubinsky et al. | Dec 2006 | A1 |
20070005053 | Dando | Jan 2007 | A1 |
20070021744 | Creighton | Jan 2007 | A1 |
20070060989 | Deem et al. | Mar 2007 | A1 |
20070066972 | Ormsby et al. | Mar 2007 | A1 |
20070129721 | Phan et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070156135 | Rubinsky et al. | Jul 2007 | A1 |
20070167740 | Grunewald et al. | Jul 2007 | A1 |
20070167940 | Stevens-Wright | Jul 2007 | A1 |
20070173878 | Heuser | Jul 2007 | A1 |
20070208329 | Ward et al. | Sep 2007 | A1 |
20070225589 | Viswanathan | Sep 2007 | A1 |
20070249923 | Keenan | Oct 2007 | A1 |
20070260223 | Scheibe et al. | Nov 2007 | A1 |
20070270792 | Hennemann et al. | Nov 2007 | A1 |
20080009855 | Hamou | Jan 2008 | A1 |
20080033426 | Machell | Feb 2008 | A1 |
20080065061 | Viswanathan | Mar 2008 | A1 |
20080086120 | Mirza et al. | Apr 2008 | A1 |
20080091195 | Silwa et al. | Apr 2008 | A1 |
20080103545 | Bolea et al. | May 2008 | A1 |
20080132885 | Rubinsky et al. | Jun 2008 | A1 |
20080161789 | Thao et al. | Jul 2008 | A1 |
20080172048 | Martin et al. | Jul 2008 | A1 |
20080200913 | Viswanathan | Aug 2008 | A1 |
20080208118 | Goldman | Aug 2008 | A1 |
20080243214 | Koblish | Oct 2008 | A1 |
20080281322 | Sherman et al. | Nov 2008 | A1 |
20080300574 | Belson et al. | Dec 2008 | A1 |
20080300588 | Groth et al. | Dec 2008 | A1 |
20090024084 | Khosla et al. | Jan 2009 | A1 |
20090048591 | Ibrahim et al. | Feb 2009 | A1 |
20090062788 | Long et al. | Mar 2009 | A1 |
20090076500 | Azure | Mar 2009 | A1 |
20090105654 | Kurth et al. | Apr 2009 | A1 |
20090138009 | Viswanathan et al. | May 2009 | A1 |
20090149917 | Whitehurst et al. | Jun 2009 | A1 |
20090163905 | Winkler et al. | Jun 2009 | A1 |
20090228003 | Sinelnikov | Sep 2009 | A1 |
20090240248 | Deford et al. | Sep 2009 | A1 |
20090275827 | Aiken et al. | Nov 2009 | A1 |
20090281477 | Mikus et al. | Nov 2009 | A1 |
20090306651 | Schneider | Dec 2009 | A1 |
20100004623 | Hamilton et al. | Jan 2010 | A1 |
20100023004 | Francischelli et al. | Jan 2010 | A1 |
20100137861 | Soroff et al. | Jun 2010 | A1 |
20100185140 | Kassab et al. | Jul 2010 | A1 |
20100185186 | Longoria | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100191232 | Boveda | Jul 2010 | A1 |
20100241185 | Mahapatra et al. | Sep 2010 | A1 |
20100261994 | Davalos et al. | Oct 2010 | A1 |
20100274238 | Klimovitch | Oct 2010 | A1 |
20100280513 | Juergen et al. | Nov 2010 | A1 |
20100280539 | Miyoshi et al. | Nov 2010 | A1 |
20100292687 | Kauphusman et al. | Nov 2010 | A1 |
20100312096 | Guttman et al. | Dec 2010 | A1 |
20100312300 | Ryu et al. | Dec 2010 | A1 |
20110028962 | Werneth et al. | Feb 2011 | A1 |
20110028964 | Edwards | Feb 2011 | A1 |
20110040199 | Hopenfeld | Feb 2011 | A1 |
20110098694 | Long | Apr 2011 | A1 |
20110106221 | Neal, II et al. | May 2011 | A1 |
20110130708 | Perry et al. | Jun 2011 | A1 |
20110144524 | Fish et al. | Jun 2011 | A1 |
20110144633 | Govari | Jun 2011 | A1 |
20110160785 | Mon et al. | Jun 2011 | A1 |
20110190659 | Long et al. | Aug 2011 | A1 |
20110190727 | Edmunds et al. | Aug 2011 | A1 |
20110213231 | Hall et al. | Sep 2011 | A1 |
20110276047 | Sklar et al. | Nov 2011 | A1 |
20110276075 | Fung et al. | Nov 2011 | A1 |
20110288544 | Verin et al. | Nov 2011 | A1 |
20110288547 | Morgan et al. | Nov 2011 | A1 |
20110313417 | De La Rama et al. | Dec 2011 | A1 |
20120029512 | Willard et al. | Feb 2012 | A1 |
20120046570 | Villegas et al. | Feb 2012 | A1 |
20120053581 | Wittkampf et al. | Mar 2012 | A1 |
20120059255 | Paul et al. | Mar 2012 | A1 |
20120071872 | Rubinsky et al. | Mar 2012 | A1 |
20120078320 | Schotzko et al. | Mar 2012 | A1 |
20120078343 | Fish | Mar 2012 | A1 |
20120089089 | Swain et al. | Apr 2012 | A1 |
20120095459 | Callas et al. | Apr 2012 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120158021 | Morrill | Jun 2012 | A1 |
20120165667 | Altmann et al. | Jun 2012 | A1 |
20120172859 | Condie et al. | Jul 2012 | A1 |
20120172867 | Ryu et al. | Jul 2012 | A1 |
20120197100 | Razavi et al. | Aug 2012 | A1 |
20120209260 | Lambert et al. | Aug 2012 | A1 |
20120220998 | Long et al. | Aug 2012 | A1 |
20120265198 | Crow et al. | Oct 2012 | A1 |
20120283582 | Mahapatra et al. | Nov 2012 | A1 |
20120303019 | Zhao et al. | Nov 2012 | A1 |
20120310052 | Mahapatra et al. | Dec 2012 | A1 |
20120310230 | Willis | Dec 2012 | A1 |
20120310237 | Swanson | Dec 2012 | A1 |
20120316557 | Sartor et al. | Dec 2012 | A1 |
20130030430 | Stewart et al. | Jan 2013 | A1 |
20130060247 | Sklar et al. | Mar 2013 | A1 |
20130060248 | Sklar et al. | Mar 2013 | A1 |
20130079768 | De Luca et al. | Mar 2013 | A1 |
20130090651 | Smith | Apr 2013 | A1 |
20130096655 | Moffitt et al. | Apr 2013 | A1 |
20130103027 | Sklar et al. | Apr 2013 | A1 |
20130103064 | Arenson et al. | Apr 2013 | A1 |
20130131662 | Wittkampf | May 2013 | A1 |
20130158538 | Govari | Jun 2013 | A1 |
20130158621 | Ding et al. | Jun 2013 | A1 |
20130172715 | Just et al. | Jul 2013 | A1 |
20130172864 | Ibrahim et al. | Jul 2013 | A1 |
20130172875 | Govari et al. | Jul 2013 | A1 |
20130184702 | Neal, II et al. | Jul 2013 | A1 |
20130218157 | Callas et al. | Aug 2013 | A1 |
20130226174 | Ibrahim et al. | Aug 2013 | A1 |
20130237984 | Sklar | Sep 2013 | A1 |
20130253415 | Sano et al. | Sep 2013 | A1 |
20130296679 | Condie et al. | Nov 2013 | A1 |
20130310829 | Cohen | Nov 2013 | A1 |
20130317385 | Sklar et al. | Nov 2013 | A1 |
20130331831 | Werneth et al. | Dec 2013 | A1 |
20130338467 | Grasse et al. | Dec 2013 | A1 |
20140005664 | Govari et al. | Jan 2014 | A1 |
20140024911 | Harlev et al. | Jan 2014 | A1 |
20140039288 | Shih | Feb 2014 | A1 |
20140051993 | McGee | Feb 2014 | A1 |
20140052118 | Laske et al. | Feb 2014 | A1 |
20140052126 | Long et al. | Feb 2014 | A1 |
20140052216 | Long et al. | Feb 2014 | A1 |
20140058377 | Deem et al. | Feb 2014 | A1 |
20140081113 | Cohen et al. | Mar 2014 | A1 |
20140100563 | Govari et al. | Apr 2014 | A1 |
20140107644 | Falwell et al. | Apr 2014 | A1 |
20140142408 | De La Rama et al. | May 2014 | A1 |
20140148804 | Ward et al. | May 2014 | A1 |
20140163480 | Govari et al. | Jun 2014 | A1 |
20140163546 | Govari et al. | Jun 2014 | A1 |
20140171942 | Werneth et al. | Jun 2014 | A1 |
20140180035 | Anderson | Jun 2014 | A1 |
20140187916 | Clark et al. | Jul 2014 | A1 |
20140194716 | Diep et al. | Jul 2014 | A1 |
20140194867 | Fish et al. | Jul 2014 | A1 |
20140200567 | Cox et al. | Jul 2014 | A1 |
20140235986 | Harlev et al. | Aug 2014 | A1 |
20140235988 | Ghosh | Aug 2014 | A1 |
20140235989 | Wodlinger et al. | Aug 2014 | A1 |
20140243851 | Cohen et al. | Aug 2014 | A1 |
20140276760 | Bonyak et al. | Sep 2014 | A1 |
20140276782 | Paskar | Sep 2014 | A1 |
20140276791 | Ku et al. | Sep 2014 | A1 |
20140288556 | Ibrahim et al. | Sep 2014 | A1 |
20140303721 | Fung et al. | Oct 2014 | A1 |
20140343549 | Spear et al. | Nov 2014 | A1 |
20140364845 | Rashidi | Dec 2014 | A1 |
20140371613 | Narayan et al. | Dec 2014 | A1 |
20150005767 | Werneth et al. | Jan 2015 | A1 |
20150011995 | Avitall et al. | Jan 2015 | A1 |
20150066108 | Shi et al. | Mar 2015 | A1 |
20150119674 | Fischell et al. | Apr 2015 | A1 |
20150126840 | Thakur et al. | May 2015 | A1 |
20150133914 | Koblish | May 2015 | A1 |
20150138977 | Dacosta | May 2015 | A1 |
20150141978 | Subramaniam et al. | May 2015 | A1 |
20150142041 | Kendale et al. | May 2015 | A1 |
20150148796 | Bencini | May 2015 | A1 |
20150150472 | Harlev et al. | Jun 2015 | A1 |
20150157402 | Kunis et al. | Jun 2015 | A1 |
20150157412 | Wallace et al. | Jun 2015 | A1 |
20150164584 | Davalos et al. | Jun 2015 | A1 |
20150173824 | Davalos et al. | Jun 2015 | A1 |
20150173828 | Avitall | Jun 2015 | A1 |
20150174404 | Rousso et al. | Jun 2015 | A1 |
20150182740 | Mickelsen | Jul 2015 | A1 |
20150196217 | Harlev et al. | Jul 2015 | A1 |
20150223726 | Harlev et al. | Aug 2015 | A1 |
20150230699 | Berul et al. | Aug 2015 | A1 |
20150258344 | Tandri et al. | Sep 2015 | A1 |
20150265342 | Long et al. | Sep 2015 | A1 |
20150265344 | Aktas et al. | Sep 2015 | A1 |
20150272656 | Chen | Oct 2015 | A1 |
20150272664 | Cohen | Oct 2015 | A9 |
20150272667 | Govari et al. | Oct 2015 | A1 |
20150282729 | Harlev et al. | Oct 2015 | A1 |
20150289923 | Davalos et al. | Oct 2015 | A1 |
20150304879 | Dacosta | Oct 2015 | A1 |
20150320481 | Cosman et al. | Nov 2015 | A1 |
20150321021 | Tandri et al. | Nov 2015 | A1 |
20150327944 | Neal, II et al. | Nov 2015 | A1 |
20150342532 | Basu et al. | Dec 2015 | A1 |
20150343212 | Rousso et al. | Dec 2015 | A1 |
20150351836 | Prutchi | Dec 2015 | A1 |
20150359583 | Swanson | Dec 2015 | A1 |
20160000500 | Salahieh et al. | Jan 2016 | A1 |
20160008061 | Fung et al. | Jan 2016 | A1 |
20160008065 | Gliner et al. | Jan 2016 | A1 |
20160029960 | Toth et al. | Feb 2016 | A1 |
20160038772 | Thapliyal et al. | Feb 2016 | A1 |
20160051204 | Harlev et al. | Feb 2016 | A1 |
20160051324 | Stewart et al. | Feb 2016 | A1 |
20160058493 | Neal, II et al. | Mar 2016 | A1 |
20160058506 | Spence et al. | Mar 2016 | A1 |
20160066993 | Avitall et al. | Mar 2016 | A1 |
20160074679 | Thapliyal et al. | Mar 2016 | A1 |
20160095531 | Narayan et al. | Apr 2016 | A1 |
20160095642 | Deno et al. | Apr 2016 | A1 |
20160095653 | Lambert et al. | Apr 2016 | A1 |
20160100797 | Mahapatra et al. | Apr 2016 | A1 |
20160100884 | Fay et al. | Apr 2016 | A1 |
20160106498 | Highsmith et al. | Apr 2016 | A1 |
20160106500 | Olson | Apr 2016 | A1 |
20160113709 | Maor | Apr 2016 | A1 |
20160113712 | Cheung et al. | Apr 2016 | A1 |
20160120564 | Kirkpatrick et al. | May 2016 | A1 |
20160128770 | Afonso et al. | May 2016 | A1 |
20160166167 | Narayan et al. | Jun 2016 | A1 |
20160166310 | Stewart et al. | Jun 2016 | A1 |
20160166311 | Long et al. | Jun 2016 | A1 |
20160174865 | Stewart et al. | Jun 2016 | A1 |
20160183877 | Williams et al. | Jun 2016 | A1 |
20160184003 | Srimathveeravalli et al. | Jun 2016 | A1 |
20160184004 | Hull et al. | Jun 2016 | A1 |
20160213282 | Leo et al. | Jul 2016 | A1 |
20160220307 | Miller et al. | Aug 2016 | A1 |
20160235470 | Callas et al. | Aug 2016 | A1 |
20160287314 | Arena et al. | Oct 2016 | A1 |
20160310211 | Long | Oct 2016 | A1 |
20160324564 | Gerlach et al. | Nov 2016 | A1 |
20160324573 | Mickelsen et al. | Nov 2016 | A1 |
20160331441 | Konings | Nov 2016 | A1 |
20160331459 | Townley et al. | Nov 2016 | A1 |
20160354142 | Pearson et al. | Dec 2016 | A1 |
20160361109 | Weaver et al. | Dec 2016 | A1 |
20170001016 | De Ridder | Jan 2017 | A1 |
20170035499 | Stewart et al. | Feb 2017 | A1 |
20170042449 | Deno et al. | Feb 2017 | A1 |
20170042615 | Salahieh et al. | Feb 2017 | A1 |
20170056648 | Syed et al. | Mar 2017 | A1 |
20170065330 | Mickelsen et al. | Mar 2017 | A1 |
20170065339 | Mickelsen | Mar 2017 | A1 |
20170065340 | Long | Mar 2017 | A1 |
20170065343 | Mickelsen | Mar 2017 | A1 |
20170071543 | Basu et al. | Mar 2017 | A1 |
20170095291 | Harrington et al. | Apr 2017 | A1 |
20170105793 | Cao et al. | Apr 2017 | A1 |
20170146584 | Daw et al. | May 2017 | A1 |
20170151029 | Mickelsen | Jun 2017 | A1 |
20170172654 | Wittkampf et al. | Jun 2017 | A1 |
20170181795 | Debruyne | Jun 2017 | A1 |
20170189097 | Viswanathan et al. | Jul 2017 | A1 |
20170215953 | Long et al. | Aug 2017 | A1 |
20170245928 | Xiao et al. | Aug 2017 | A1 |
20170246455 | Athos et al. | Aug 2017 | A1 |
20170312024 | Harlev et al. | Nov 2017 | A1 |
20170312025 | Harlev et al. | Nov 2017 | A1 |
20170312027 | Harlev et al. | Nov 2017 | A1 |
20180001056 | Leeflang et al. | Jan 2018 | A1 |
20180042674 | Mickelsen | Feb 2018 | A1 |
20180042675 | Long | Feb 2018 | A1 |
20180043153 | Viswanathan et al. | Feb 2018 | A1 |
20180064488 | Long et al. | Mar 2018 | A1 |
20180085160 | Viswanathan et al. | Mar 2018 | A1 |
20180093088 | Mickelsen | Apr 2018 | A1 |
20180133460 | Townley et al. | May 2018 | A1 |
20180168511 | Hall et al. | Jun 2018 | A1 |
20180184982 | Basu et al. | Jul 2018 | A1 |
20180193090 | de la Rama et al. | Jul 2018 | A1 |
20180200497 | Mickelsen | Jul 2018 | A1 |
20180214195 | Fraasch et al. | Aug 2018 | A1 |
20180214202 | Howard et al. | Aug 2018 | A1 |
20180221078 | Howard et al. | Aug 2018 | A1 |
20180243558 | Athos et al. | Aug 2018 | A1 |
20180250508 | Howard | Sep 2018 | A1 |
20180289417 | Schweitzer et al. | Oct 2018 | A1 |
20180303488 | Hill | Oct 2018 | A1 |
20180303543 | Stewart et al. | Oct 2018 | A1 |
20180311497 | Viswanathan et al. | Nov 2018 | A1 |
20180344393 | Gruba et al. | Dec 2018 | A1 |
20180360534 | Teplitsky et al. | Dec 2018 | A1 |
20190038171 | Howard | Feb 2019 | A1 |
20190060632 | Asirvatham et al. | Feb 2019 | A1 |
20190069950 | Viswanathan et al. | Mar 2019 | A1 |
20190125439 | Rohl et al. | May 2019 | A1 |
20190151015 | Viswanathan et al. | May 2019 | A1 |
20190183378 | Mosesov et al. | Jun 2019 | A1 |
20190192223 | Rankin | Jun 2019 | A1 |
20190201089 | Waldstreicher et al. | Jul 2019 | A1 |
20190209238 | Jimenez | Jul 2019 | A1 |
20190223938 | Arena et al. | Jul 2019 | A1 |
20190223950 | Gelbart et al. | Jul 2019 | A1 |
20190231421 | Viswanathan et al. | Aug 2019 | A1 |
20190231425 | Waldstreicher et al. | Aug 2019 | A1 |
20190233809 | Neal, II et al. | Aug 2019 | A1 |
20190256839 | Neal, II et al. | Aug 2019 | A1 |
20190269912 | Viswanathan et al. | Sep 2019 | A1 |
20190328445 | Sano et al. | Oct 2019 | A1 |
20190336198 | Viswanathan et al. | Nov 2019 | A1 |
20190336207 | Viswanathan | Nov 2019 | A1 |
20190350647 | Ramberg et al. | Nov 2019 | A1 |
20190376055 | Davalos et al. | Dec 2019 | A1 |
Number | Date | Country |
---|---|---|
1042990 | Oct 2000 | EP |
1125549 | Aug 2001 | EP |
0797956 | Jun 2003 | EP |
1127552 | Jun 2006 | EP |
1340469 | Mar 2007 | EP |
1009303 | Jun 2009 | EP |
2213729 | Aug 2010 | EP |
2425871 | Mar 2012 | EP |
1803411 | Aug 2012 | EP |
2532320 | Dec 2012 | EP |
2587275 | May 2013 | EP |
2663227 | Nov 2013 | EP |
1909678 | Jan 2014 | EP |
2217165 | Mar 2014 | EP |
2376193 | Mar 2014 | EP |
2708181 | Mar 2014 | EP |
2777579 | Sep 2014 | EP |
2934307 | Oct 2015 | EP |
2777585 | Jun 2016 | EP |
2382935 | Mar 2018 | EP |
3111871 | Mar 2018 | EP |
3151773 | Apr 2018 | EP |
3056242 | Jul 2018 | EP |
H06-507797 | Sep 1994 | JP |
H10-510745 | Oct 1998 | JP |
2000-508196 | Jul 2000 | JP |
2005-516666 | Jun 2005 | JP |
2006-506184 | Feb 2006 | JP |
2007-325935 | Dec 2007 | JP |
2008-538997 | Nov 2008 | JP |
2009-500129 | Jan 2009 | JP |
2011-509158 | Mar 2011 | JP |
2012-050538 | Mar 2012 | JP |
WO 9207622 | May 1992 | WO |
WO 9221278 | Dec 1992 | WO |
WO 9221285 | Dec 1992 | WO |
WO 9407413 | Apr 1994 | WO |
WO 9724073 | Jul 1997 | WO |
WO 9725917 | Jul 1997 | WO |
WO 9737719 | Oct 1997 | WO |
WO 1999004851 | Feb 1999 | WO |
WO 1999022659 | May 1999 | WO |
WO 1999056650 | Nov 1999 | WO |
WO 1999059486 | Nov 1999 | WO |
WO 2002056782 | Jul 2002 | WO |
WO 2003053289 | Jul 2003 | WO |
WO 2003065916 | Aug 2003 | WO |
WO 2004045442 | Jun 2004 | WO |
WO 2004086994 | Oct 2004 | WO |
WO 2005046487 | May 2005 | WO |
WO 2006115902 | Nov 2006 | WO |
WO 2007006055 | Jan 2007 | WO |
WO 2007079438 | Jul 2007 | WO |
WO 2009082710 | Jul 2009 | WO |
WO 2009089343 | Jul 2009 | WO |
WO 2009137800 | Nov 2009 | WO |
WO 2010014480 | Feb 2010 | WO |
WO 2011028310 | Mar 2011 | WO |
WO 2011154805 | Dec 2011 | WO |
WO 2012051433 | Apr 2012 | WO |
WO 2012153928 | Nov 2012 | WO |
WO 2013019385 | Feb 2013 | WO |
WO 2014025394 | Feb 2014 | WO |
WO 2014031800 | Feb 2014 | WO |
WO 2014036439 | Mar 2014 | WO |
WO 2014160832 | Oct 2014 | WO |
WO 2015066322 | May 2015 | WO |
WO 2015099786 | Jul 2015 | WO |
WO 2015103530 | Jul 2015 | WO |
WO 2015103574 | Jul 2015 | WO |
WO 2015130824 | Sep 2015 | WO |
WO 2015140741 | Sep 2015 | WO |
WO 2015143327 | Sep 2015 | WO |
WO 2015171921 | Nov 2015 | WO |
WO 2015175944 | Nov 2015 | WO |
WO 2015192018 | Dec 2015 | WO |
WO 2015192027 | Dec 2015 | WO |
WO 2016059027 | Apr 2016 | WO |
WO 2016060983 | Apr 2016 | WO |
WO 2016081650 | May 2016 | WO |
WO 2016090175 | Jun 2016 | WO |
WO 2017093926 | Jun 2017 | WO |
WO 2017119934 | Jul 2017 | WO |
WO 2017120169 | Jul 2017 | WO |
WO 2017192477 | Nov 2017 | WO |
WO 2017192495 | Nov 2017 | WO |
WO 2017218734 | Dec 2017 | WO |
WO 2018005511 | Jan 2018 | WO |
WO 2018200800 | Nov 2018 | WO |
WO 2018208795 | Nov 2018 | WO |
WO 2019118436 | Jun 2019 | WO |
WO 2019133606 | Jul 2019 | WO |
WO 2019133608 | Jul 2019 | WO |
WO 2019147832 | Aug 2019 | WO |
WO 2019152986 | Aug 2019 | WO |
WO 2019173309 | Sep 2019 | WO |
Entry |
---|
Partial Supplementary European Search Report for European Application No. 13827672.0, dated Mar. 23, 2016, 6 pages. |
Supplementary European Search Report for European Application No. 13827672.0, dated Jul. 11, 2016, 12 pages. |
Office Action for European Application No. 13827672.0, dated Feb. 5, 2018, 6 pages. |
Notice of Reasons for Rejection for Japanese Application No. 2015-526522, dated Mar. 6, 2017, 3 pages. |
Office Action for U.S. Appl. No. 14/400,455, dated Mar. 30, 2017, 10 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/031252, dated Jul. 19, 2013, 12 pages. |
Office Action for U.S. Appl. No. 15/819,726, dated Jun. 4, 2018, 17 pages. |
Office Action for U.S. Appl. No. 15/917,194, dated Jun. 4, 2018, 17 pages. |
Office Action for U.S. Appl. No. 15/917,194, dated Oct. 9, 2018, 13 pages. |
First Office Action for Chinese Application No. 201580006848.8, dated Jan. 29, 2018, 15 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Dec. 17, 2018, 17 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2018/050660, dated Nov. 26, 2018, 13 pages. |
Office Action for European Application No. 15701856.5, dated Dec. 11, 2017, 6 pages. |
Notice of Reasons for Rejection for Japanese Application No. 2016-544072, dated Oct. 1, 2018, 11 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/010138, dated Mar. 26, 2015, 14 pages. |
International Preliminary Report on Patentability for International Application No. PCT/US2015/010138, dated Jul. 12, 2016, 9 pages. |
Supplementary European Search Report for European Application No. 15733297.4, dated Aug. 10, 2017, 7 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Apr. 3, 2017, 6 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Aug. 29, 2017, 12 pages. |
Office Action for U.S. Appl. No. 15/201,997, dated Jul. 12, 2018, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/010223, dated Apr. 10, 2015, 19 pages. |
International Preliminary Report on Patentability for International Application No. PCT/US2015/010223, dated Jul. 12, 2016, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/029734, dated Nov. 24, 2015, 15 pages. |
Office Action for U.S. Appl. No. 15/795,062, dated Dec. 19, 2017, 14 pages. |
Office Action for U.S. Appl. No. 15/795,062, dated Apr. 9, 2018, 20 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/031086, dated Oct. 21, 2015, 16 pages. |
Office Action for U.S. Appl. No. 15/795,075, dated Feb. 6, 2018, 9 pages. |
Office Action for U.S. Appl. No. 15/795,075, dated Jun. 15, 2018, 10 pages. |
Extended European Search Report for European Application No. 15849844.4, dated May 3, 2018, 8 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/055105, dated Mar. 1, 2016, 15 pages. |
Office Action for U.S. Appl. No. 15/796,255, dated Jan. 10, 2018, 12 pages. |
Extended European Search Report for European Application No. 15806855.1, dated Jan. 3, 2018, 8 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/035582, dated Oct. 2, 2015, 17 pages. |
Extended European Search Report for European Application No. 15806278.6, dated Feb. 9, 2018, 5 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2015/035592, dated Oct. 2, 2015, 13 pages. |
Office Action for U.S. Appl. No. 15/334,646, dated Jul. 25, 2017, 19 pages. |
Office Action for U.S. Appl. No. 15/334,646, dated Nov. 16, 2017, 26 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2016/057664, dated Feb. 24, 2017, 11 pages. |
Office Action for U.S. Appl. No. 15/796,375, dated Jan. 24, 2018, 25 pages. |
Office Action for U.S. Appl. No. 15/796,375, dated May 30, 2018, 26 pages. |
Office Action for U.S. Appl. No. 15/796,375, dated Nov. 16, 2018, 27 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2017/012099, dated May 18, 2017, 17 pages. |
Office Action for U.S. Appl. No. 15/711,266, dated Feb. 23, 2018, 14 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2018/029938, dated Aug. 29, 2018, 14 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2017/037609, dated Nov. 8, 2017, 13 pages. |
Office Action for U.S. Appl. No. 15/672,916, dated Feb. 13, 2018, 16 pages. |
Office Action for U.S. Appl. No. 15/672,916, dated Jul. 20, 2018, 23 pages. |
Office Action for U.S. Appl. No. 15/499,804, dated Jan. 3, 2018, 20 pages. |
Office Action for U.S. Appl. No. 15/794,717, dated Feb. 1, 2018, 10 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2018/029552, dated Jun. 29, 2018, 13 pages. |
Office Action for U.S. Appl. No. 15/970,404, dated Oct. 9, 2018, 21 pages. |
du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013). |
Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages. |
Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007]. |
Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016). |
Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014). |
Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014). |
Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014). |
van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014). |
van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015). |
Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012). |
Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011). |
Office Action for Canadian Application No. 2,881,462, dated Mar. 19, 2019, 5 pages. |
Office Action for Japanese Application No. 2018-036714, dated Jan. 16, 2019, 8 pages. |
Office Action for U.S. Appl. No. 15/201,983, dated Apr. 3, 2019, 16 pages. |
Office Action for U.S. Appl. No. 15/341,523, dated Jan. 29, 2019, 10 pages. |
Office Action for U.S. Appl. No. 15/795,075, dated Apr. 10, 2019, 11 pages. |
Office Action for U.S. Appl. No. 15/672,916, dated Apr. 9, 2019, 31 pages. |
Partial European Search Report for European Application No. 18170210.1, dated Feb. 14, 2019, 13 pages. |
Office Action for U.S. Appl. No. 15/970,404, dated Apr. 12, 2019, 20 pages. |
Office Action for U.S. Appl. No. 15/917,194, dated Apr. 29, 2019, 10 pages. |
Office Action for U.S. Appl. No. 15/795,062, dated May 3, 2019, 21 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/014226, dated Apr. 29, 2019, 15 pages. |
Extended European Search Report for European Application No. 18189811.5, dated May 14, 2019, 7 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/017322, dated May 10, 2019, 15 pages. |
Office Action for U.S. Appl. No. 15/341,512, dated Aug. 1, 2019, 19 pages. |
Office Action for U.S. Appl. No. 15/341,523, dated Jul. 30, 2019, 8 pages. |
Office Action for U.S. Appl. No. 15/795,075, dated Jul. 31, 2019, 12 pages. |
Office Action for U.S. Appl. No. 15/484,969, dated Sep. 4, 2019, 12 pages. |
Office Action for U.S. Appl. No. 15/354,475, dated May 23, 2019, 7 pages. |
Extended European Search Report for European Application No. 16884132.8, dated Jul. 8, 2019, 7 pages. |
Office Action for U.S. Appl. No. 16/416,677, dated Aug. 15, 2019, 8 pages. |
Extended European Search Report for European Application No. 17736218.3 dated Aug. 23, 2019, 9 pages. |
Office Action for U.S. Appl. No. 16/181,027, dated Sep. 4, 2019, 12 pages. |
Office Action for U.S. Appl. No. 16/240,066, dated May 29, 2019, 7 pages. |
Extended European Search Report for European Application No. 18170210.1, dated May 17, 2019, 11 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/030922, dated Sep. 6, 2019, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/030882, dated Sep. 10, 2019, 17 pages. |
Office Action for U.S. Appl. No. 16/405,515, dated Sep. 6, 2019, 9 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/031135, dated Aug. 5, 2019, 11 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/028943, dated Sep. 17, 2019, 17 pages. |
Extended European Search Report for European Application No. 19182099.2, dated Dec. 13, 2019, 7 pages. |
Office Action for Japanese Application No. 2018-036714, dated Nov. 27, 2019, 5 pages. |
Office Action for U.S. Appl. No. 15/917,194, dated Dec. 20, 2019, 10 pages. |
Office Action for U.S. Appl. No. 15/201,983, dated Nov. 15, 2019, 15 pages. |
Office Action for U.S. Appl. No. 15/341,512, dated Nov. 12, 2019, 18 pages. |
Office Action for U.S. Appl. No. 15/795,062, dated Nov. 4, 2019, 23 pages. |
Office Action for U.S. Appl. No. 16/375,561, dated Oct. 17, 2019, 15 pages. |
Office Action for U.S. Appl. No. 15/970,404, dated Nov. 12, 2019, 19 pages. |
Office Action for U.S. Appl. No. 16/573,704, dated Dec. 17, 2019, 6 pages. |
Office Action for U.S. Appl. No. 16/723,407, dated Mar. 19, 2020, 13 pages. |
Tekle, E. et al., “Electroporation by using bipolar oscillating electric field: An improved method for DNA transfection of NIH 3T3 cells,” Proc. Natl. Acad. Sci. USA, vol. 88, pp. 4230-4234, May 1991. |
Office Action for U.S. Appl. No. 16/722,650, dated Mar. 25, 2020, 12 pages. |
Number | Date | Country | |
---|---|---|---|
Parent | 16573704 | Sep 2019 | US |
Child | 16741506 | US |